Bharat Immunological & Biological Corporation Ltd Net Loss is INR -1.89 crores in Q3 FY 2020-2021

Bharat Immunological & Biological Corporation Ltd Q3 FY20-21 Quarter Result

Bharat Immunological & Biological Corporation Ltd Net Loss is INR -1.89 crores in Quarter 3, October – December of Financial Year 2020-2021.

Quarterly Net Earnings Year-on-Year

Bharat Immunological & Biological Corporation Ltd Quarter Net Loss is widen by -20 % from Last Year Quarter and Net Loss of INR -1.89 crores is reported in Quarter 3, October – December of Financial Year 2020-2021. Last Year Quarter 3, October – December of Financial Year 2019-2020sa Net Loss was INR -2.35 crores.

Quarterly Net Sales Year-on-Year

Bharat Immunological & Biological Corporation Ltd Quarter Sale is down -12 % from Last Year Quarter.

Annual Sales & Net Earning

Bharat Immunological & Biological Corporation Ltd Annual Sales in Financial Year 2019 to 2020 was reported INR 83.65 crores and Annual Profit in Financial Year 2019 to 2020 was reported INR -5.79 crores.


Bharat Immunological & Biological Corporation Ltd Stock Information

SectorPharmaceuticals
IndustryPharmaceuticals – Indian – Formulations
AboutBharat Immunologicals and Biologicals Corporation is an India-based biotechnology company. The Company manufactures and produces a range of pharmaceuticals products, such as Oral Polio Vaccines (OPV Vaccine), Zinc Tablet and Diarrhea Management Kit (Zinc Tablet + oral rehydration salts (ORS)).
Latest Qaurter EPS-0.4376964967437682

Bharat Immunological & Biological Corporation Ltd Stock Analysis:

Get more Quarterly Earnings Results of companies

Get complete data on Bharat Immunological & Biological Corporation Ltd

Leave a Comment

Your email address will not be published.